DUBLIN – Less than a week after Dendreon Corp. gained historic FDA approval, on April 29, 2010, for Provenge (sipuleucel-T) to treat prostate cancer, a group of scientists attached to Etablissement Français du Sang (EFS), the French blood transfusion service, and their collaborators published details of a cancer vaccine strategy based on a novel dendritic cell line derived from patients with a rare form of leukemia.